Metrics as of 10/13/2026, 06:52 PM (Berlin time), refresh in progress.
Larimar Therapeutics Stock
Larimar Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Carole S. Ben-Maimon
- Employees
- 71
- Market cap
- $220 M
- IPO
- 19/06/2014
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is…
Larimar Therapeutics stock: price history
1D
-1.6%
1W
-22.7%
1M
-43.8%
6M
-56.0%
YTD
-44.2%
1Y
-45.5%
2Y
-70.7%
5Y
-82.5%
10Y
-94.9%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~25% stronger price swings than usual
Ask the agents about Larimar Therapeutics
Analyst assessment of Larimar Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$8.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 05/08/2026
Larimar Therapeutics stock metrics
P/E
-1.06
P/B
1.72
EV/EBITDA
-0.77
RETURN ON EQUITY
-25.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.7%
FLOAT SHARES
59,939,814
AVG. DAILY VOLUME (30D)
1,289,705
Insider transactions (SEC)
Harlow John B. Jr.
Hamilton Thomas Edward
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Larimar Therapeutics stock
What does Larimar Therapeutics do?
Larimar Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Carole S. Ben-Maimon, the company employs around 71 people.
The IPO was on 19/06/2014; the stock trades on NASDAQ under the ticker LRMR.
What do analysts say about Larimar Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 05/08/2026).
The average price target is US$8.00, ranging from US$5.00 to US$11.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Larimar Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does Larimar Therapeutics pay a dividend?
No, Larimar Therapeutics currently does not pay a dividend.
Which stocks are comparable to Larimar Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Larimar Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Larimar Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.